Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$139.94 USD

139.94
992,667

+4.27 (3.15%)

Updated Oct 8, 2024 04:00 PM ET

After-Market: $140.00 +0.06 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Higher production costs are a woe.

Catalent (CTLT) Inks Deal With MigVax for Oral COVID-19 Vaccine

by Zacks Equity Research

Catalent's (CTLT) latest agreement is expected to significantly boost global COVID-19 vaccination drives.

BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox

by Zacks Equity Research

BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.

Veeva Systems (VEEV) Unveils New Study Training Application

by Zacks Equity Research

Veeva Systems' (VEEV) new clinical study training application will address the demands and complexities involved in present-day trials.

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

PerkinElmer (PKI) Unveils New NGS System to Aid Genomic Analysis

by Zacks Equity Research

PerkinElmer's (PKI) introduction of the RUO BioQule NGS System is a cost-effective system that can bring improvements in genomic analysis.

BD (BDX) to Expand Base in Pharmacy Automation With New Buyout

by Zacks Equity Research

BD's (BDX) buyout of Parata Systems is expected to advance its 2025 strategy to accelerate innovation in smart, connected care and enabling new care settings.

Here's Why You Should Retain AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

HealthEquity (HQY) Q1 Earnings Lag Estimates, FY23 View Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust segmental revenues, in the first quarter of fiscal 2023.

Here's Why You Should Hold on to Avanos (AVNS) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.

Here's Why You Should Retain ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies. However, limited commercial expertise is a woe.

Cardinal Health (CAH) to Extend Warehouse Footing With New Center

by Zacks Equity Research

Cardinal Health's (CAH) new distribution center to support the company's at-Home Solutions business.

BD's (BDX) Latest Product to Transform Research Outcome

by Zacks Equity Research

BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting as well as provide answers to previously unthinkable questions.

Cooper Companies (COO) Q2 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

Despite a decline in the bottom line, Cooper Companies' (COO) fiscal second-quarter earnings reflect solid segmental performance.

Accuray's (ARAY) New Tie-Up to Augment Treatment Planning

by Zacks Equity Research

Accuray (ARAY) partners with Limbus AI to enhance the treatment planning process and patient care.

Veeva Systems (VEEV) Beats on Q1 Earnings, Ups FY23 View

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both of its segments.

Why Is Masimo (MASI) Up 6.9% Since Last Earnings Report?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

DexCom (DXCM) to Boost Diabetes Management With New Coverage

by Zacks Equity Research

DexCom's (DXCM) G6 CGM System gets public coverage through Prince Edward Island's Diabetes Glucose Sensor Program, which can aid in effective diabetes management.

    Abbott (ABT) Receives FDA Nod for FreeStyle Libre 3 System

    by Zacks Equity Research

    Abbott's (ABT) FreeStyle Libre 3 system offers greater accuracy and easier application compared with other CGMs.

    Here's Why Investors Should Retain Integra (IART) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about Integra's (IART) better-than-expected results and strong performance across several geographies.

    Here's Why You Should Retain QuidelOrtho (QDEL) Stock For Now

    by Zacks Equity Research

    Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

    Here's Why Investors Should Retain Cerner (CERN) Stock Now

    by Zacks Equity Research

    Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.

    Stryker's (SYK) Q Guidance System Receives FDA Approval

    by Zacks Equity Research

    Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during image-guided surgery following the receipt of the FDA approval.